• organizations:EyePoint Pharmaceuticals
EyePoint doses first patient in second phase 3 trial of DURAVYU for wet AMD
Pipeline

EyePoint doses first patient in second phase 3 trial of DURAVYU for wet AMD

As the company’s second global phase 3 trial, LUCIA is evaluating vorolanib intravitreal insert when injected every 6 months versus aflibercept.
EyePoint doses first patient in global phase 3 wet AMD trial of Duravyu
Pipeline

EyePoint doses first patient in global phase 3 wet AMD trial of Duravyu

LUGANO study is evaluating the continuous durability of the vorolanib intravitreal insert when injected every 6 months versus aflibercept.
EyePoint fails to meet primary goal in phase 2 NPDR trial
Pipeline

EyePoint fails to meet primary goal in phase 2 NPDR trial

Interim 9-month data finds DURAVYU demonstrated a continued favorable safety profile and tolerability similar to its other indications for DME and wet AMD.
Positive topline data reported in EyePoint's phase 2 wet AMD trial
Pipeline

Positive topline data reported in EyePoint's phase 2 wet AMD trial

EYP-1910 demonstrates a favorable safety profile in DAVIO 2 study, meeting all endpoints.
EyePoint Pharmaceuticals names new CEO
Business

EyePoint Pharmaceuticals names new CEO

Effective July 10, the company’s former COO Jay S. Duker, MD, has assumed leadership.
EyePoint concludes enrollment for phase 2 PAVIA trial for NPDR
Pipeline

EyePoint concludes enrollment for phase 2 PAVIA trial for NPDR

EYP-1901 is being assessed as a potential nine-month, sustained-delivery treatment.
Alimera purchases US commercial rights to YUTIQ
Business

Alimera purchases US commercial rights to YUTIQ

Acquisition from EyePoint Pharmaceuticals gives the company exclusive global rights.